Clinical Utility of Whole Breast Screening Ultrasound in Patients Undergoing Digital Breast Tomosynthesis
Completed
- Conditions
- Breast Screening
- Interventions
- Procedure: breast ultrasoundProcedure: DBT (Full field digital mammography + tomosynthesis)
- Registration Number
- NCT02174406
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Brief Summary
The purpose of this study is to determine whether ultrasound or Digital breast tomosynthesis (DBT) detects more cancers and to compare the types of cancers detected on ultrasound and DBT.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 1494
Inclusion Criteria
- Any women scheduled for screening WBUS and a screening FFDM on the same day or within the following 30 days of each other.
Read More
Exclusion Criteria
- Age < 30 years old
- Male patients
- Patients with any clinical symptoms (palpable mass, nipple discharge, etc)
- Patients with known cancer
- Patients with any breast surgery or biopsy within 90 days prior to the study
- Patients with breast implants
- Patients pregnant or lactating
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description women scheduled for breast screening breast ultrasound Each patient will have the following: * Screening whole breast ultrasound * DBT (Full field digital mammography + tomosynthesis views in the CC and MLO projections). The only change in patient management will be the addition of digital breast tomosynthesis views in patients scheduled for FFDM alone. DBT is currently clinically approved and being offered on a voluntary basis to patients scheduled for FFDM. women scheduled for breast screening DBT (Full field digital mammography + tomosynthesis) Each patient will have the following: * Screening whole breast ultrasound * DBT (Full field digital mammography + tomosynthesis views in the CC and MLO projections). The only change in patient management will be the addition of digital breast tomosynthesis views in patients scheduled for FFDM alone. DBT is currently clinically approved and being offered on a voluntary basis to patients scheduled for FFDM.
- Primary Outcome Measures
Name Time Method estimate the cancer detection rates 2 years The detection rate of each imaging test is defined as the proportion of patients who are positive on that imaging test who truly have the disease compared to the total number of women screened. A positive imaging test is defined as a test with a recommendation for biopsy (BI-RADS 4 or 5).
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States